Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity

Kewal Asosingh, Hendrik De Raeeve, Eline Menu, Ivan Van Riet, Eric Van Marck, Benjamin Van Camp, and Karin Vanderkerken

The active role of angiogenesis during disease progression is well recognized in solid tumors. In hematologic malignancies such as multiple myeloma (MM), it is not known whether tumor neovascularization is an epiphenomenon or whether it is actively involved in disease progression. At clinical presentation, myeloma disease and the associated angiogenesis are both well established. Here the 5T2MM murine model was used to analyze angiogenesis during preclinical myeloma stages. Bone marrow (BM) of 5T2MM-inoculated mice was analyzed at weekly intervals until the end stage of the disease. Histologic analysis and assessment of microvessel density (MVD) by CD31 staining demonstrated a preangiogenic stage of small tumor aggregates followed by an angiogenic switch and subsequently an angiogenic stage of progressive tumor growth and large, confluent tumor nodules. Flow cytometric analysis that indicated an increase in percentage CD45+ MM cells preceded the angiogenic switch. Real-time polymerase chain reaction (RT-PCR) of sorted CD45+ and CD45− MM cells indicated higher vascular endothelial growth factor 120 (VEGF120) and VEGF164 transcripts in CD45− MM cells. VEGF enzyme-linked immunosorbent assay (ELISA) revealed high secretion by CD45− MM cells but no protein secretion by CD45+ MM cells, indicating angiogenic heterogeneity among the MM cells. These data suggest that, like in solid tumors, angiogenic switch and angiogenic heterogeneity exist in MM. (Blood. 2004;103:3131-3137)

Introduction

Angiogenesis or neovascularization is a multistep process of new blood vessel formation from existing blood vessels and is indispensable for physiologic growth, tissue healing, and regeneration. Neovascularization is also an essential process during tumorigenesis. Like normal tissues, tumor cells require an adequate supply of oxygen, nutrients, and an effective way to dispose of toxic metabolites. Generally, tumor masses beyond 0.5 mm in diameter require neovascularization for their survival and progressive growth.1-3 For few tumors, however, the preexisting vessels are sufficient.4-6 In solid tumors, the active role of neovascularization during tumorigenesis is well recognized.7 Increased angiogenesis in several human solid tumors has been associated with poor clinical outcome8-14 and plays a crucial role in their progressive growth and metastasis.15-17 Solid tumor progression is characterized by an avascular phase of slow tumor growth and a vascular phase of rapid tumor progression and metastasis. In the dormant, avascular stage, the tumor nodules are small enough to allow diffusion of oxygen from preexisting capillaries to the cancer cells; however, for their further progression the induction of a tumor vasculature must take place. This initiation of tumor vasculature termed “angiogenic switch” is orchestrated by a balance between proangiogenic and antiangiogenic molecules.7,18 From the several angiogenic activators described,7 vascular endothelial growth factor (VEGF) is an essential regulator of vascularization and is indispensable for both developmental and tumor angiogenesis.19-22 VEGF acts as an endothelial cell survival, mitogenic, and chemotactic factor23 and induces vessel destabilization by the induction of angiopoietin-2 in endothelial cells, resulting in angiogenic sprouting.24 Three isoforms of VEGF occur by alternative splicing of the mRNA: 121-, 165-, and 189-amino acid proteins (in mouse 120, 164, and 188 residues, respectively).25 In humans, VEGF206, a very rare form, has also been described.26 Although angiogenesis has been reported in hematologic (“liquid”) malignancies,27 it is not clear whether the neovascularization is actively involved in the disease progression or is merely an epiphenomenon. Multiple myeloma (MM) is such a “liquid” malignancy and is characterized by expansion and accumulation of monoclonal plasma cells in the bone marrow (BM). Several groups have reported an increased angiogenesis during clinical MM progression associated with proliferation of the MM cells and adverse clinical prognosis.28-32 In addition, the transition from monoclonal gammopathy to MM, accounting for one third of the new MM cases, is associated with an increased neovascularization.28,33 Myeloma cells express VEGF,34,35 and elevated serum levels of VEGF have been associated with increased BM angiogenesis29 and a higher MM cell labeling index.30,36 However, at clinical presentation myeloma disease as well as the associated angiogenesis are both well established, and whether the angiogenesis is an epiphenomenon or an important...
step in myeloma pathogenesis is unclear. In a previous work our group demonstrated in the 5T2MM experimental mouse model that preclinical myeloma disease progression is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis. In this work the 5T2MM model was used to investigate angiogenesis during the initial, preclinical, stages of MM. Based on histologic, microvessel density (MVD), and flow cytometric analyses, we herein report a preangiogenic stage of slow myeloma progression, followed by an angiogenic switch and subsequent angiogenic stages of progressive tumor growth. The angiogenic switch was preceded by an increase in percentage CD45−MM cells. Real-time polymerase chain reaction (PCR) of flow cytometric–sorted CD45− and CD45+ MM cells indicated a higher number of VEGF mRNA copies in the CD45− MM cells. Analysis of conditioned media from sorted CD45+ and CD45− MM cells by enzyme-linked immunosorbent assay (ELISA) revealed high VEGF secretion by the CD45− MM cells but no detectable secretion by the CD45+ MM cells.

Materials and methods

5T2MM myeloma model

5T2 multiple myeloma cells originate from spontaneously developed myeloma in elderly C57BL/6J mice. The model was initiated and is continued by intravenous injection of disease BM cells into young (6- to 10-week-old) syngeneic recipients (Harlan, Horst, The Netherlands) as described previously. Study design

Thirty-three mice were intravenously injected with 2 × 106 5T2MM cells, and from the onset of the experiment 3 mice were killed each week until the terminal stage of the disease. From each mouse, paraprotein (serum concentration of monoclonal antibodies secreted by the MM cells) and tumor load were quantified and the MM cells were phenotyped. One hind leg was processed for histologic analysis and CD31 staining. In a second part of the study, MM cells were sorted for in vitro experiments. Serum paraprotein quantification and isolation of BM cells

Mice were bled before killing, and serum paraprotein concentration was quantified by electrophoresis. BM cells were flushed out from femora and tibiae, and BM mononuclear cells (BMNCs) were isolated by centrifugation of the cell suspension on Lympholyte M (Cedarlane, Hornby, ON, Canada).

Histologic analysis and assessment of microvessel density

One hind of each mouse was fixed by immersion in zinc fixative (0.1 M Tris [tris(hydroxymethyl)aminomethane] buffer, pH 7.4, recipe above) for 48 hours and decalcified in a decalcification solution (100 g EDTA [ethylenediaminetetraacetic acid], 12 g NaOH, 50 mL formalin 40%, 950 mL demineralized water) for 4 days. Samples were embedded in paraffin, and 5-μm sections were made by a rotation microtome (Microm HM335, Walldorf, Germany). Of each sample step, sections were made. One slide was stained with hematoxylin and eosin. On the next slide, an immunostain was performed by staining of the BMNCs with monoclonal antibodies (clone BRD.3, mouse IgG1) (Biosource International) according to the manufacturer’s instructions. Rat antimouse IgG1-phycocerythrin (IgG1-PE) (Becton Dickinson) was used as secondary reagent.

CD31 immunostaining. For CD31 immunostaining the sections were deparaffinized. The endogenous peroxidase was quenched by incubating the slides in 50 mL methanol, 0.5 mL H2O2 (30%) solution for 30 minutes. Trypsinization (Trypsin 1019819; Roche, Manheim, Germany) for 20 minutes at 37°C was used for antigen retrieval. The slides were preincubated with normal goat serum for 30 minutes. The primary antibody CD31 (platelet endothelial cell adhesion molecule-1 [PECAM-1]; Becton Dickson, San Jose, CA) was incubated overnight at 4°C at a dilution of 1:10. As secondary antibody biotin-conjugated goat antirat-specific polyclonal IgG (554014; Becton Dickinson Pharmingen) was used in a dilution of 1:75. The Tyramide Signal Amplification (TSA; NEN Life Science Products, Boston, MA) was used to enhance the signal intensity. Chromogenic visualization was accomplished through the use of a streptavidin–horseradish peroxidase conjugate, followed by diaminobenzidine. The sections were counterstained with Carazzi hematoxylin. As negative controls, isotype-matched irrelevant antibodies were used.

Flow cytometry

Tumor load in the BM was quantified by staining of the BMNCs with anti-CD11c antibodies (IB4B, mouse immunoglobulin G1; IgG1). Rat antimouse IgG1–peridinin chlorophyll protein (IgG1-PerCP) (Becton Dickinson) was used as a second step. Rat antimouse CD45–fluorescein isothiocyanate (CD45-FITC; clone AM54508; Bio-source International, Camarillo, CA) was used to analyze CD45 expression on the MM cells. Isotype-matched irrelevant antibodies were used as negative controls. All samples were analyzed on a FACS Calibur flow cytometer (Becton Dickinson), and all cell sortings were performed on a FACS Vantage–SE flow cytometer (Becton Dickinson). Myeloma cells were selected by sequential gating of 5T2MM idiotype-positive cells as described in detail previously. Sorted 5T2MM idiotype-positive cells were examined by light microscopy after May–Grünewald–Giemsa staining to confirm their identity as true MM cells.

Bromodeoxyuridine incorporation

Bromodeoxyuridine incorporation was performed to analyze the proliferation of the MM cells during disease progression. Total MM cell populations from different disease stages were sorted as described previously. A quantity of 0.25 × 106 cells was incubated for 1 hour in Dulbecco modified essential medium (DMEM) supplemented with penicillin-streptomycin, glutamine, minimum essential medium (MEM) (GIBCO, Merelbeke, Belgium), and 10% bovine serum (HyClone, Logan, UT) with 12.5 μg/mL bromodeoxyuridine (BrdU) (Sigma, St Louis, MO). Cells incubated in medium without BrdU were used as control. After incubation, the cells were stained for flow cytometric analysis with anti-BrdU monoclonal antibodies (clone BRD.3, mouse IgG1) (Biosource International) according to the manufacturer’s instructions. Rat antimouse IgG1-phycocerythrin (IgG1-PE) (Becton Dickinson) was used as secondary reagent.

Quantitative RT-PCR

To analyze VEGF mRNA expression by MM cells, real-time (RT)–PCR was performed. Total RNA was extracted from flow cytometric–sorted CD45− and CD45+ MM cells using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and converted into cDNA using the SuperScript First-Strand Synthesis System (Invitrogen Life Technologies, Merelbeke, Belgium), according to the manufacturer’s instructions. Primers and probes used for VEGF120 and VEGF164 have been described by others. For both isofoms the common forward primer 5′-ACAGCAGATGTGAATGCGAC-3′ and the common forward primer 5′-GCCGACACATA-GAGGAATGAGC-3′ were used. As reverse primers, 5′-CGGCTTGTCATAC-1TTTCTGG-3′ and 5′-CAAGGTCAACAGTATTGCTG-3′ were used for VEGF120 and VEGF164, respectively. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as endogenous reference gene to standardize for the amount of sample RNA. GAPDH primers and probes were purchased from ABI (Foster City, CA) and used according to the manufacturer’s instructions. VEGF and GAPDH probes were labeled.
with tetramethylrhodamine (TAMRA) quencher dye and FAM (6-carboxyfluorescein) (for VEGF) or VIC (for GAPDH) reporter dyes. Taqman PCR was performed in a 25-µL reaction mix containing 12.5 µL 2 × Master Mix (ABI), 200 nM probe, 300 nM forward primer, 300 nM reverse primer, and 50 ng sample cDNA. PCR cycles consisted of an initial denaturation step at 95°C for 10 minutes followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. Each sample was amplified in triplicate. For relative standard curves cDNA from 5T33MMvivo cells (50, 10, 2, 0.4, and 0.083 ng) were used. Measurement of gene expression was performed using the ABI PRISM 7700 Sequence Detector. The relative standard curve method was used to quantitate the relative VEGF mRNA expression.

VEGF ELISA

Secretion of VEGF by MM cells was analyzed by ELISA. Flow cytometric–sorted CD45+ and CD45− MM cells were incubated in DMEM supplemented with penicillin-streptomycin, glutamine, and MEM at a cell concentration of 1 × 10^7/mL. After 24 hours, conditioned media were collected after centrifugation of the cells. VEGF ELISA was performed using the Quantikine M, mouse VEGF ELISA kit (R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions. With this ELISA, VEGF164 and VEGF120 are detected with a lower detection limit of 3.0 pg/mL.

Statistical analysis

StatView 5.0.1 software (SAS Institute, Cary, NC) was used for statistical analysis. Simple regression analysis was performed to calculate correlations. Mann-Whitney U test was used for the comparison of 2 means. P < .05 or less were considered as significant.

Results

Angiogenesis and tumor growth during 5T2MM disease progression

Naive mice were intravenously injected with 5T2MM cells, and each week 3 animals were analyzed until all animals were terminally diseased. In Figure 1 the evolution of the tumor load during the disease progression is illustrated. Myeloma cells were detectable by flow cytometry 4 weeks after tumor inoculation. As recently described by our group, 7 3 disease stages were distinguished: a quiescent stage, an intermediate stage, and an end stage of slow, moderate, and accelerated tumor growth, respectively. MVD during the disease progression was analyzed by CD31 staining of the BM samples. Normal BM vasculature consists of a complex sinusoidal network that becomes part of the tumor vasculature during progressive tumor growth. Because in this stage it is difficult to distinguish between the newly formed blood vessels (angiogenesis) and the preexisting blood vessels, the latter were included in the assessment of MVD. There was a good correlation between the MVD and the tumor load, paraprotein concentration, and percentage BrdU-positive MM cells (Figure 2). These correlations are in line with clinical observations in human MM28-30 confirming the strength of the 5T2MM model.

Histologic analysis (Figure 3A) indicated different patterns of tumor infiltration in the different disease stages. In the quiescent stage, individual cells were observed from day 28, and from day 35 small (fewer than 50 cells) aggregates of MM cells were formed. By the end of this dormant phase, larger (more than 50 cells) tumor aggregates were found. These aggregates did not disturb the architecture of the preexisting sinusoidal vessels. The major part of the quiescent stage was characterized by a constant MVD at the level of normal BM vasculature (Figure 3B). At the end of this stage, between day 42 and day 49, a clear onset in the increase of
the MVD was observed, indicating an angiogenic switch. During the subsequent angiogenic stage (intermediate and end stage), progressive tumor growth was observed, as indicated by flow cytometric analyses of the tumor load (Figure 1). This was confirmed by histologic examination of animals in intermediate and end stage, demonstrating the presence of confluent tumor nodules, followed by subtotal infiltration and diffuse infiltration of the BM (Figure 3B). During this angiogenic stage, the MVD further increased parallel with the tumor growth (Figure 3). Compared with the preangiogenic sinusoids, the microvessels of the tumor-infiltrated areas were smaller with a slitlike lumen and immunostained more intense for CD31. All together, these data clearly indicate that 5T2MM disease progression is characterized by a preangiogenic stage of slow tumor progression, followed by an angiogenic switch and a subsequent angiogenic stage of progressive tumor growth.

**Increase in percentage CD45⁻ 5T2MM cells precedes the angiogenic switch**

In analogy to human MM, 5T2MM cells have a heterogeneous CD45 expression. Recently we reported that preclinical 5T2MM disease progression is a process of ongoing differentiation of CD45⁺ MM cells into CD45⁻ cells. In the end stage of the disease (corresponding to the human situation at clinical presentation) most 5T2MM cells are CD45⁻. Because angiogenic heterogeneity among cancer cells has been reported for solid tumors, we analyzed whether the angiogenic switch was associated with the presence of CD45⁻ MM cells. Flow cytometric analysis (Figure 4A) indicated that the angiogenic switch was preceded by an increase in the percentage CD45⁻ MM cells. Most of the myeloma cell population during the angiogenic stage consisted of CD45⁻ MM cells. When the MVD was plotted against the percentage CD45⁻ MM cells, it became clear that the angiogenic switch did not occur until the percentage CD45⁻ MM cells had reached a threshold value (Figure 4B). There was also a significant difference between the percentage CD45⁻ MM cells and between the MVD before and after the angiogenic switch (Table 1). These data demonstrate that the angiogenic switch coincides with an increased proportion of CD45⁻ MM cells in the myeloma population.

**Expression of VEGF by CD45⁺ and CD45⁻ 5T2MM cells**

VEGF is an essential factor for both normal and tumor-associated angiogenesis; therefore, we analyzed whether there was any difference in the expression of this key regulator of neovascularization between the CD45⁺ and the CD45⁻ MM cells. In analogy to human MM cells, 5T2MM cells express VEGF120 and
Table 1. MVD and % CD45− MM cells of 18 mice in the preangiogenic stage and 15 mice in the angiogenic stage

<table>
<thead>
<tr>
<th></th>
<th>Preangiogenic stage</th>
<th>Angiogenic stage</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>MVD, no. of blood</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vessels/0.20 mm²</td>
<td>14.9 (11-17.1)</td>
<td>27.6 (24.5-45)</td>
<td>&lt;.009</td>
</tr>
<tr>
<td>% CD45− MM cells</td>
<td>40.8 (31.4-68.2)</td>
<td>79.2 (73.9-84.5)</td>
<td>&lt;.03</td>
</tr>
</tbody>
</table>

Values presented are medians, with ranges in parentheses.

Discussion

Unlike in solid tumors, the role of angiogenesis in the pathogenesis of hematologic malignancies such as MM is a subject of debate.28-30 At the time of diagnosis, the myeloma disease as well as the associated angiogenesis are both well established. Insights into the early, preclinical tumor stages and neovascularization would clarify the role of angiogenesis in myeloma pathobiology. Such an investigation requires an in vivo model, and for this purpose we used the 5T2MM model in this work. This murine model has clinical symptoms similar to human myeloma.47-49 In addition, we demonstrated in this work that, like in the human situation,28-30 a good correlation exists between the MVD and the tumor load, the serum paraprotein levels, and the proliferation of the 5T2MM cells.

As reported in a previous work,37 a quiescent stage of slow tumor progression and 2 progressive stages of moderate and accelerated tumor growth—intermediate and end stage, respectively—could be distinguished during 5T2MM tumorigenesis. The early, quiescent stage was a preangiogenic phase of slow tumor progression within the network of preexisting BM sinusoidal capillaries. During this stage the MM cells were found as single cells, small aggregates of few cells, or as larger but still separated aggregates at the end of the preangiogenic stage. These aggregates did not interfere with the architecture of the sinusoidal vessels. The myeloma cell population consisted of mainly CD45+/− MM cells, which exhibited undetectable VEGF secretion. In this stage BrdU incorporation by MM cells was low, indicating a low proliferative rate, as reported previously.37 Myeloma disease progression is a process of ongoing differentiation of CD45+/− MM cells into CD45− MM cells.37 By the end of the preangiogenic stage, most of the MM cells were CD45− with high levels of VEGF secretion. At this time point the angiogenic switch was observed as a significant increase in the MVD. In the subsequent angiogenic stage a progressive expansion of the tumor was observed. The tumor load increased progressively, and the MM growth pattern consisted of confluent tumor nodules, followed by subtotal and diffuse infiltration of the BM. In line with these findings, we reported that MM cells in the intermediate and end stage exhibit a high proliferation as indicated by BrdU incorporation.37 These data are completely in line with the occurrence of angiogenesis during solid tumorigenesis. In early stages of solid tumor growth there is a preangiogenic stage of dormant, slow tumor progression. In this stage the preexisting vessels of the host tissue are sufficient to maintain the tumor (co-option). During the preangiogenic phase the tumor population consists of only few angiogenic cancer cells (cancer cells with the capacity to induce neovascularization). When enough cancer cells become angiogenic, angiogenic switch occurs, followed by a vascular stage of progressive tumor expansion and metastasis.7,50 Most, if not all, cases of myeloma...
angiogenic activity, resulting in slow-growing tumors; and nonaggressive, aggressive tumors; subpopulations with weakly angiogenic capacity, giving rise to slow-growing, aggressive tumors; subpopulations with weakly angiogenic activity, resulting in slow-growing tumors; and nonangiogenic subpopulations that remain stable tumors. Our data suggest that in MM, CD45+ MM cells are the angiogenic subpopulation and indicate that the concept of angiogenic heterogeneity is also applicable for myeloma disease. In keeping with these findings, we recently reported that a minority of 5T2-MM-bearing mice have a slow disease progression associated with the presence of high proportions of CD45+ MM cells.51

Angiogenic switch is induced when the balance of angiogenic inhibitors and activators is changed by overexpression of proangiogenic factors.7 VEGF is one of the most essential activators of both normal and tumor angiogenesis and acts on the endothelial cells via VEGF receptors (VEGFRs). VEGFR-2 is the most important for the angiogenic switch.52 Like human BM endothelial cells,53 mouse BM endothelial cells also express VEGFR-2, as indicated by flow cytometric analysis of immortalized BM endothelial cells, STR-4, STR-10, and STR-12 54 (data not shown), suggesting that endothelial cells in the BM are prone to VEGF. The loss of a single VEGF allele results in severely impaired vascularization and early embryonic lethality.19,20 Cancer cells knocked out for the VEGF gene have a dramatically decreased vascular density and a greatly reduced tumor growth when inoculated in vivo.21,22 From these latter works it became clear that tumor-derived VEGF plays a crucial role in tumor angiogenesis, and these works settled the debate of the relative contribution of cancer cell versus normal host cell VEGF expression to tumor growth.21,22 The angiopoietin/Tie-2 system plays also a crucial role in angiogenesis.55 Angiopoietin-1 and -2 have Tie-2 as common receptor on the endothelial cells. Angiopoietin-1 maintains and stabilizes mature vessels, while its natural antagonist, angiopoietin-2, desaturates the vessels and induces angiogenic sprouting. Recent insights indicate that angiopoietin-2 is induced in the endothelial cells by tumor-derived VEGF determining the angiopoietin/Tie-2 balance in favor of angiogenesis.24 The expression of angiopoietin-2 and Tie-2 by BM endothelial cells in human myeloma has been well documented.53,56

At clinical presentation, most human MM cells are CD45−, which is also observed in the 5T2-MM model.37 5T2-MM cells express VEGF120 and VEGF164 isoforms, another analogy to the human MM cells.32,35 Overexpression of specific VEGF isoforms in fibrosarcomas knocked out for the VEGF gene has demonstrated that each isoform has a unique role in tumor angiogenesis.22 VEGF-null fibrosarcomas failed to induce tumor vascularization, resulting in a significant reduction of tumor size compared with the wild type. VEGF120 overexpression recruited peripheral host blood vessels to the periphery of the tumor but induced only limited vascularization of the tumor itself, also resulting in highly decreased tumor growth. VEGF164 was the only isoform that recruited host blood vessels and induced tumor microvasculature, fully restoring the tumor-associated angiogenesis and tumor expansion. When mice were inoculated with a mixture of different VEGF isoform transfectants, VEGF164-expressing cancer cells exhibited the most rapid expansion. These data indicated that during tumorigenesis selective pressure favors the cancer cells expressing VEGF164. Our observation of increasing CD45− MM cell compartment during the disease progression is also in line with this finding in solid tumors. Recently, CD45− phenotype appeared to be a predictor of poor clinical outcome in human57 and 5T2-MM myelomas.51 Antiangiogenic therapy in MM has been suggested by several groups33,35,58,59; however, our data indicate the existence of a preangiogenic stage. This raises the possibility that antiangiogenic drugs alone may not be fully curative because MM cells in this stage are angiogenic independent and can survive within the network of normal BM vasculature.

All together, the data in this work indicate important similarities between angiogenesis in solid tumor and angiogenesis in MM. The existence of a preangiogenic stage of slow tumor progression, mainly consisting of MM cells with no detectable VEGF secretion, and the increase in VEGF-producing MM cells preceding the angiogenic switch and the subsequent angiogenic stage of progressive tumor expansion suggest that, as in solid tumors, angiogenesis is an active and important process in myeloma disease progression.

Acknowledgments

The authors thank Gunther Vrolix, Liliane Moeneclaey, and Frank Rylant for the histologic sections and immunostainings.

References


Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990; 82:4-6.


Angiogenic switch during 5T2MM murine myeloma tumorogenesis: role of CD45 heterogeneity

Kewal Asosingh, Hendrik De Raeve, Eline Menu, Ivan Van Riet, Eric Van Marck, Benjamin Van Camp and Karin Vanderkerken

Updated information and services can be found at: http://www.bloodjournal.org/content/103/8/3131.full.html

Articles on similar topics can be found in the following Blood collections
  - Hemostasis, Thrombosis, and Vascular Biology (2485 articles)
  - Immunobiology and Immunotherapy (5501 articles)
  - Neoplasia (4182 articles)

Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml